This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Shalvata Mental Health Center, Hod Hasharon, Israel
9 March, 2009
A double-blind placebo-controlled clinical trial utilizing the Brainsway®’s Deep TMS device for the treatment of negative symptoms in 45 patients with schizophrenia has begun at the Shalvata Mental Health Center.
The trial began on March 2009, and is expected to be carried out over the course of 7 weeks in respect of each subject.
This trial is expected to serve as the basis for a broad multi-center trial.